Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Not yet recruiting 2Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

CNS 5Sarcoma 1Lymphoid 1

Conditions

Glioblastoma 5Recurrence 3Glioma 3Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2Neoplasms 1Lymphoma, Follicular 1Lung Neoplasms 1Gliosarcoma 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Central Nervous System Neoplasms 1

Interventions

Temozolomide 405Radiotherapy 202Bevacizumab 157Radiation 80Magnetic Resonance Spectroscopy 77Lomustine 49Surgical Procedures, Operative 45Carmustine 41pembrolizumab 40Irinotecan 38Nivolumab 32Specimen Handling 28Carboplatin 27Radiosurgery 24Erlotinib Hydrochloride 24Drug Therapy 23Chemotherapy, Adjuvant 23Radiotherapy, Intensity-Modulated 22Cyclophosphamide 20Aminolevulinic Acid 20O(6)-benzylguanine 17sargramostim 16Radiotherapy, Conformal 15Blood Specimen Collection 15temsirolimus 14Granulocyte-Macrophage Colony-Stimulating Factor 14Everolimus 14Vorinostat 13Sorafenib 13Ipilimumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Glioblastoma × cemiplimab × CNS × Clear all
NCT07620548 2026-06-02

Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent Glioblastomas

Washington University School of Medicine

Phase 2 Not yet recruiting
99 enrolled
CNS

Glioblastoma, Recurrence

NCT07422363 2026-05-13

Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma

National Cancer Institute (NCI)

Phase 1 Not yet recruiting
30 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT03491683 2026-05-04

INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

Inovio Pharmaceuticals

Phase 1/2 Active not recruiting
52 enrolled
CNS

Glioblastoma

NCT04826393 2025-10-22

ASP8374 + Cemiplimab in Recurrent Glioma

Dana-Farber Cancer Institute

Phase 1 Completed
14 enrolled
CNSLymphoid

Glioblastoma, Glioma, Lymphoma, Follicular

NCT04006119 2025-04-18

Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma

Alaunos Therapeutics

Phase 2 Terminated
40 enrolled 14 charts
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡